Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Seeks Japan Nod for Vonvendi Use in Patients Under 18
Takeda Pharmaceutical said on June 10 that it has filed Vonvendi (vonicog alfa), a treatment for von Willebrand disease (VWD), for an additional dosage regimen for patients under the age of 18. The submission is primarily based on data from…
To read the full story
Related Article
BUSINESS
- Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
March 27, 2026
- Ono Files Japan NDA For Deciphera-Originated GIST Drug Qinlock
March 27, 2026
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- Asahi Kasei Banks on Tarpeyo to Hit 300 Billion Yen in Pharma Sales by FY2030
March 26, 2026
- Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…